Eli Lilly is making its biggest investment yet in U.S. drug manufacturing, announcing plans to spend at least $27 billion to build four new plants. The move will more than double its domestic investment since 2020, bringing its total spending to over $50 billion—the largest pharmaceutical manufacturing expansion in U.S. history. The company expects the new sites to create 3,000 full-time jobs for engineers, scientists, and technicians, plus 10,000 construction jobs as the facilities are built.
“We’re making these investments … to prepare for the demand we anticipate for future pipeline medicines a…
Comments are closed, but trackbacks and pingbacks are open.